Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia.
AuthorsSmits, Evelien L.J.
Hardwick, Nicola R.
Brooks, Suzanne E.
Van Tendeloo, Viggo F.I.
Orchard, Kim H.
AffiliationUniversity of Antwerp
MetadataShow full item record
AbstractImmunotherapy is currently under active investigation as an adjuvant therapy to improve the overall survival of patients with acute myeloid leukaemia (AML) by eliminating residual leukaemic cells following standard therapy. The graft-versus-leukaemia effect observed following allogeneic haematopoietic stem cell transplantation has already demonstrated the significant role of immune cells in controlling AML, paving the way to further exploitation of this effect in optimized immunotherapy protocols. In this review, we discuss the current state of cellular immunotherapy as adjuvant therapy for AML, with a particular focus on new strategies and recently published results of preclinical and clinical studies. Therapeutic vaccines that are being tested in AML include whole tumour cells as an autologous source of multiple leukaemia-associated antigens (LAA) and autologous dendritic cells loaded with LAA as effective antigen-presenting cells. Furthermore, adoptive transfer of cytotoxic T cells or natural killer cells is under active investigation. Results from phase I and II trials are promising and support further investigation into the potential of cellular immunotherapeutic strategies to prevent or fight relapse in AML patients.
CitationSmits, E.L.J., Lee, C., Hardwick, N., Brooks, S.E., Van Tendeloo, V.F.I., Orchard, K., Guinn, B.A. (2011) 'Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia' Cancer immunology, immunotherapy, 60 (6):757-69
SponsorsLeukaemia and Lymphoma Research, Cancer Research U.K.
- Immunotherapy prospects for acute myeloid leukaemia.
- Authors: Barrett AJ, Le Blanc K
- Issue date: 2010 Aug
- Peptide vaccines for patients with acute myeloid leukemia.
- Authors: Schmitt M, Casalegno-Garduño R, Xu X, Schmitt A
- Issue date: 2009 Oct
- The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
- Authors: Grabrucker C, Liepert A, Dreyig J, Kremser A, Kroell T, Freudenreich M, Schmid C, Schweiger C, Tischer J, Kolb HJ, Schmetzer H
- Issue date: 2010 Jun
- Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.
- Authors: van de Loosdrecht AA, van den Ancker W, Houtenbos I, Ossenkoppele GJ, Westers TM
- Issue date: 2009
- Immunotherapy of acute myeloid leukemia: current approaches.
- Authors: Smits EL, Berneman ZN, Van Tendeloo VF
- Issue date: 2009 Mar